H. pylori Clarithromycin Resistance Tops 42% in Real-World Cohort Study

Nearly half of all Helicobacter pylori patients who underwent susceptibility testing at a Romanian tertiary-care center were resistant to at least one antibiotic, according to a new cohort study published in Microorganisms. The findings, drawn from 352 adults treated between November 2022 and November 2025, put clarithromycin resistance at 42.5% – more than twice the 15% ceiling above which European guidelines say empirical clarithromycin-based triple therapy should no longer be used. The numbers sharpen an already urgent conversation about whether clinicians can keep reaching for the same antibiotic playbook they have used for decades.

Clarithromycin Resistance Makes Standard Triple Therapy Obsolete

The headline number is 42.5% clarithromycin resistance across the 168 patients who received culture and antibiotic susceptibility testing. Metronidazole resistance followed at 36.4%, and levofloxacin resistance stood at 14.0%. Amoxicillin fared far better, with only 2.4% of isolates showing resistance, and rifampicin resistance was rare at 1.7%. Overall, 44.6% of susceptibility-tested patients carried at least one resistant strain, and 12.5% met the definition of multidrug resistance (MDR), meaning their bacteria were unresponsive to two or more drug classes simultaneously. The dominant MDR pattern was dual clarithromycin-metronidazole resistance, which is precisely the combination that underpins the most widely used empirical regimens. A global systematic review and meta-analysis has already flagged H. pylori resistance as reaching alarming levels worldwide; this Romanian dataset confirms the trend is playing out at the bedside, not just in pooled statistics.

Why Prior Eradication Therapy Changes the Odds So Sharply

The single strongest predictor of resistance was a history of previous H. pylori eradication treatment. Patients who had been treated before showed overall resistance in 63.2% of cases, compared with 39.2% in treatment-naive patients (p = 0.006). The gap was even clearer for clarithromycin specifically: 60.5% resistance in previously treated patients versus 34.6% in first-timers (p = 0.006). MDR rates followed the same pattern, rising from 7.7% in naive patients to 28.9% in those with prior treatment (p = 0.001). Multivariable logistic regression confirmed that prior eradication therapy was an independent predictor of resistance, with an adjusted odds ratio of 2.41 (95% CI 1.29 to 4.51; p = 0.006). Demographic factors, including age and sex, showed no significant association with resistance. The practical message is that a patient's treatment history is a clinical warning sign, not background noise. When someone has already failed one eradication attempt, the probability that their strain carries resistance has roughly doubled, and rising clarithromycin and levofloxacin resistance globally means this problem is not unique to any one country or hospital.

How a Real-World Tertiary-Care Cohort Captured Resistance Rates

Matei, Suciu, Ilias, Avram, Suteu and colleagues conducted a retrospective observational study at a single tertiary-care center in Romania, enrolling 352 confirmed H. pylori-positive adults over three years. Of these, 168 patients underwent culture and antibiotic susceptibility testing while 184 received empirical therapy without susceptibility data. Resistance rates were calculated using available-case analysis for each antimicrobial agent, and multivariable logistic regression identified independent predictors after adjusting for potential confounders. The retrospective design is a recognized limitation: chart-based data carry the inherent biases of any observational study, and the authors acknowledge that results from a single tertiary center may not generalize to primary care settings or to regions with different prescribing histories and local epidemiology. Still, real-world data of this kind capture the everyday clinical picture more faithfully than controlled trial populations, making the resistance proportions directly relevant to practicing gastroenterologists.

Open Questions About Generalizability and Surveillance Gaps

The single-center, single-region scope is the study's most important caveat. Resistance rates vary substantially across Europe and globally, and a tertiary referral population skews toward more complex or treatment-refractory cases, which could inflate the resistance figures compared to a general community sample. The study also could not fully account for antibiotic exposures outside the H. pylori context: patients who took fluoroquinolones or macrolides for respiratory or urinary tract infections may carry pre-selected resistant strains without any prior H. pylori treatment. That confounder is difficult to capture retrospectively. What the data do not yet tell clinicians is how resistance profiles shift over time within the same cohort, or whether stewardship interventions at the institutional level move the numbers. Answering those questions requires prospective surveillance systems that link prescribing data to resistance outcomes across multiple sites.

Resistance-Informed Treatment and the Road Ahead for H. pylori Eradication

The authors conclude that clarithromycin resistance at 42.5% firmly disqualifies empirical clarithromycin-based triple therapy for this population. Their recommendation aligns with a stewardship-oriented model: culture and susceptibility testing before treatment whenever feasible, with antibiotic selection guided by the patient's actual resistance profile rather than regional assumptions. For patients who have already failed eradication, the data argue strongly against re-using regimens in the clarithromycin-metronidazole class. Bismuth-based quadruple therapy and rifabutin-based rescue regimens retain activity in most resistant isolates and represent sensible alternatives. Longer-term, researchers are exploring approaches that go beyond conventional antibiotics entirely: probiotics, phage therapy, and vaccine candidates are all active areas of investigation aimed at boosting eradication rates without driving further resistance selection. None of those options is ready for routine clinical use, but the pressure to develop them is growing in direct proportion to the resistance figures coming out of studies like this one. For now, the most actionable takeaway is straightforward: treat a patient's eradication history as a resistance risk flag, test when you can, and update your empirical defaults to match local data rather than older guidelines written when clarithromycin still worked most of the time.